The effect of gonadotropin-releasing hormone analog treatment (leuprolide) on body fat distribution in idiopathic central precocious puberty

Turkish Journal of Pediatrics

Volumn 53, Issue 1, 2011, Pages 27-33

  Taşcilar, Mehmet Emre ^a   Bilir, Pelin ^b   Akinci, Ayşehan ^c   Köse, Kenan ^b   Akçora, Dilek ^b   Inceogǎlu, Deniz ^b   Fiẗz, Suat Ömer ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c INONU UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Body fat composition; Body mass index; Hyperinsulinism; Leuprolide; Obesity; Precocious puberty

Indexed keywords

GONADORELIN DERIVATIVE; LEUPRORELIN; FERTILITY PROMOTING AGENT;

ARTICLE; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMPEDANCE; INSULIN RESISTANCE; PRECOCIOUS PUBERTY; SIDE EFFECT; TREATMENT DURATION; TRUNK; WEIGHT GAIN; BODY MASS; CHILD; PATHOPHYSIOLOGY;

BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS INDEX; CHILD; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; LEUPROLIDE; PUBERTY, PRECOCIOUS;

EID: 79958712295     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008; 159 (Suppl): S3-8.
2. Brämswig J, Dübbers A. Disorders of pubertal development. Dtsch Arztebl Int 2009; 106: 295-303.
3. Prete G, Couto-Silva AC, Trivin C, Brauner R. Idiopathic central precocious puberty in girls: presentation factors. BMC Pediatr 2008; 4: 8-27.
4. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med 2008; 358: 2366-2377.
5. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab 2004; 89: 3644-3650.
6. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999; 84: 4583-4590.
7. Sigurjonsdottir TJ, Hayles AB. Precocious puberty. A report of 96 cases. Am J Dis Child 1968; 115: 309-321.
8. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004; 10: 135-147.
9. Johansson T, Ritzen EM. Very long-term follow-up of girls with early and late menarche. Endocr Dev 2005; 8: 126-136.
10. Tremblay L, Frigon JY. Precocious puberty in adolescent girls: a biomarker of later psychosocial adjustment problems. Child Psychiatry Hum Dev 2005; 36: 73-94.
11. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girlswith idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93: 190-195.
12. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl 2008; 10: 525-534.
13. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N for the Triptorelin 3-month CPP Study Group. Three-month sustained-release Triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006; 154: 119-124.
14. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92: 1697-1704.
15. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck KS. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002; 87: 506-512.
16. Partsch JC, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol 2002; 56: 129-148.
17. Magiakou MA, Manousaki D, Papadaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010; 95: 109-117.
18. Tung YC, Lee JS, Tsai WY, Hsiao PH. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J Formos Med Assoc 2007; 106: 826-831.
19. Głab E, Barg E, Wikiera B, Grabowski M, Noczyńska A. Influence of GnRH analog therapy on body mass in central precocious puberty. Pediatr Endocrinol Diabetes Metab 2009; 15: 7-11.
20. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123: e752-762.
21. Chiocca E, Dati E, Baroncelli GI, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology 2009; 89: 441-447.
22. Arrigo T, De Luca F, Antoniazzi F, et al. Reduction of baseline body mass index under gonadotropinsuppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004; 150: 533-537.
23. Oostdijk W, Rikken B, Screuder S, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996; 75: 292-297.
24. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metabol 1995; 80: 546-551.
25. Boot AM, de Muinck KS, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious puberty and early puberty. J Clin Endocrinol Metab 1998; 83: 370-373.
26. Feuillan PP, Jones JV, Barnes K, Oerter KK, Cutler GB. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metabol 1999; 84: 44-49.
27. Palmert MR, Mansfield MJ, Crowley WF, Crigler JF, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84: 4480-4488.
28. Rodríguez PN, Bermúdez EF, Rodríguez GS, et al. Body composition by simple anthropometry, bioimpedance and DXA in preschool children: interrelationships among methods. Arch Argent Pediatr 2008; 106: 102-109.
29. Haroun D, Croker H, Viner RM, et al. Validation of BIA in obese children and adolescents and re-evaluation in a longitudinal study. Obesity 2009; 17: 2245-2250.
30. Pescovitz OH, Eugster AE. Pediatric Endocrinology. Philadelphia: Lippincott Williams & Wilkins; 2004: 316-333.
31. Partsch CJ, Hümmelink R, Lorenzen F, Sippell WG. The significance and characteristics of the LHRH test in diagnosing precocious puberty development in girls: the stimulated LH/FSH quotient differentiates between central precocious puberty and premature thelarche. Monatsschr Kinderheilkd 1989; 137: 284-288.
32. Pescovitz OH, Hench KD, Barnes KM, Loriaux DL, Cutler GB. Premature menarche and central precocious puberty: the relationship between clinical presentation and the gonadotropin response to luteinizing-hormone releasing hormone. J Clin Endocrinol Metabol 1988; 67: 474-479.
33. Bundak R, Furman A, Günöz H, Darendeliler F, Baş F, Neyzi O. Body mass index references for Turkish children. Acta Paediatr 2006; 95: 194-198.
34. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005; 115: 500-503.
35. Suleymanoglu S, Tascilar E, Pirgon O, Tapan S, Meral C, Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009; 84: 325-328.
36. Semiz S, Ozgoren E, Sabir N, Semiz E. Body fat distribution in childhood obesity: association with metabolic risk factors. Indian Pediatr 2008; 45: 457-462.
37. Pescovitz OH, Eugster AE. Pediatric Endocrinology. Philadelphia: Lippincott Williams & Wilkins; 2004: 345-362.
38. Innes EK, Selfe TK, Taylor AG. Menopause, the metabolic syndrome, and mind-body therapies. Menopause 2008; 15: 1005-1013.
39. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002; 15: 79-82.
40. Richman RA, Underwood LE, French FS, Van Wyk JJ. Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity. J Pediatr 1971; 79: 963-971.
41. Lee JM. Insulin resistance in children and adolescence. Rev Endoc Metab Disord 2006; 7: 141-147.